c4c submits a shared response to the FDA consultation

On behalf of European Rare Disease community, c4c submits a shared response to the FDA consultation about a global clinical trials network in rare diseases.   On May 29th this year, the FDA opened a consultation to obtain information and comments from patients, patient advocates, the scientific community, health professionals, other regulatory and health authorities in the…